These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16468035)

  • 21. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
    Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
    Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
    Powell DJ; Rosenberg SA
    J Immunother; 2004; 27(1):36-47. PubMed ID: 14676632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
    Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
    J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
    Spranger S; Spaapen RM; Zha Y; Williams J; Meng Y; Ha TT; Gajewski TF
    Sci Transl Med; 2013 Aug; 5(200):200ra116. PubMed ID: 23986400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
    Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
    Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
    Yee C; Thompson JA; Byrd D; Riddell SR; Roche P; Celis E; Greenberg PD
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16168-73. PubMed ID: 12427970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.
    Rivoltini L; Carrabba M; Huber V; Castelli C; Novellino L; Dalerba P; Mortarini R; Arancia G; Anichini A; Fais S; Parmiani G
    Immunol Rev; 2002 Oct; 188():97-113. PubMed ID: 12445284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine.
    Chiong B; Wong R; Lee P; Delto J; Scotland R; Lau R; Weber J
    J Immunother; 2004; 27(5):368-79. PubMed ID: 15314545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates.
    Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D
    Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
    Blank C; Brown I; Peterson AC; Spiotto M; Iwai Y; Honjo T; Gajewski TF
    Cancer Res; 2004 Feb; 64(3):1140-5. PubMed ID: 14871849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay.
    Griffioen M; Borghi M; Schrier PI; Osanto S
    Int J Cancer; 2001 Aug; 93(4):549-55. PubMed ID: 11477559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
    Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T
    J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
    Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
    J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
    Rosenberg SA; Sherry RM; Morton KE; Scharfman WJ; Yang JC; Topalian SL; Royal RE; Kammula U; Restifo NP; Hughes MS; Schwartzentruber D; Berman DM; Schwarz SL; Ngo LT; Mavroukakis SA; White DE; Steinberg SM
    J Immunol; 2005 Nov; 175(9):6169-76. PubMed ID: 16237114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
    Lee PP; Yee C; Savage PA; Fong L; Brockstedt D; Weber JS; Johnson D; Swetter S; Thompson J; Greenberg PD; Roederer M; Davis MM
    Nat Med; 1999 Jun; 5(6):677-85. PubMed ID: 10371507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
    Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
    J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.